PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington’s Disease Program

September 23, 2021

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington’s Disease Program News provided by Sep 20, 2021, 16:34 ET Share this article Share this article
SOUTH PLAINFIELD, N.J. , Sept. PTC Therapeutics, Inc. (NASDAQ: PTCT ) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

Read the source article at PR Newswire
2021-09-21 00:34:00

Share This Story!